Titanium Dioxide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Titanium Dioxide: From [No Approved Indication] to Drug-Induced Osteoporosis
One-Sentence Summary
Titanium dioxide is a pharmaceutical excipient/colorant with no approved therapeutic indication and no known mechanism of action. The TxGNN model predicts a possible association with Drug-Induced Osteoporosis, but 0 clinical trials and 0 publications currently support this direction — the prediction is unvalidated by any biological or clinical evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not applicable (excipient/colorant, no therapeutic indication) |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Titanium dioxide is not a therapeutic drug in the conventional sense — it is widely used as an inert excipient (opacifier/colorant) in tablet coatings and other pharmaceutical formulations. It has no established pharmacodynamic activity, receptor target, or metabolic pathway relevant to bone metabolism.
The TxGNN model’s top prediction (Drug-Induced Osteoporosis, score 99.9998%) is derived purely from knowledge-graph relational patterns rather than any known biological mechanism. Because titanium dioxide’s original indications list is empty and its MOA is a confirmed data gap, there is no pharmacological basis to explain why this compound would influence osteoporosis pathophysiology.
Reviewing all 10 top-ranked predicted indications for this candidate (osteoporosis, diabetic retinopathy, and multiple cataract subtypes), the pattern is consistent: high TxGNN scores are not accompanied by any clinical trials, and the sparse literature identified (5 papers under diabetic retinopathy) uses TiO2 nanoparticles purely as laboratory/imaging tools (e.g., extracellular vesicle purification, fluorescein conjugate imaging), not as therapeutic agents. This strongly suggests the TxGNN association reflects graph-topology co-occurrence (e.g., TiO2 nanoparticles appearing frequently in biomedical research contexts) rather than genuine drug-disease therapeutic relevance.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature is available for the top-ranked indication (Drug-Induced Osteoporosis). For reference, the rank-2 prediction (diabetic retinopathy) returned 5 papers, but all are non-therapeutic technical/methods papers (TiO2 nanoparticles used as tools for EV purification, retinal imaging agents, or in a general nanoparticle-diabetes mechanism review) rather than evidence supporting therapeutic use — see table below for completeness:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41637842 | 2026 | Review | J Trace Elem Med Biol | Reviews metallic nanoparticles (incl. TiO2) as tools/agents in diabetes research; not a treatment study |
| 39566751 | 2025 | Technical/Imaging | Methods (San Diego) | TiO2 nanoparticle-fluorescein conjugates evaluated as imaging agents for fundus angiography, not therapy |
| 38078945 | 2023 | Methods/Technical | Analytical Chemistry | TiO2 microparticles used as a purification tool for circulating RNA analysis |
| 36197877 | 2022 | Methods/Technical | Analytical Chemistry | TiO2 microparticles used to purify plasma extracellular vesicles for biomarker discovery |
| 20059246 | 2009 | Technical/Device | J Biomed Optics | Eye phantom device for retinal oximetry calibration; unrelated to TiO2 pharmacology |
None of these papers provide treatment or efficacy evidence for any predicted indication.
US Market Information
No approved marketing authorizations found. Titanium dioxide is currently 未上市 (Not Marketed) with 0 total licenses on record for this candidate.
Safety Considerations
Please refer to the package insert for safety information.
Note: Regulatory warning/contraindication data (DG001) is flagged as a Blocking data gap — this candidate has not entered safety screening (S1), and MOA data (DG002) is a High-severity gap affecting mechanistic assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: No original indication, no MOA, no clinical trials, and no supportive literature exist for any of the 10 top predicted indications. The high TxGNN scores reflect knowledge-graph pattern association only (Evidence Level L5) and lack any biological plausibility check — this candidate has not progressed past decision stage S0.
To proceed, the following is needed:
- Resolve DG001 (blocking): obtain TFDA/FDA label warnings and contraindications before any safety screening (S1) can begin
- Resolve DG002: obtain confirmed mechanism of action from DrugBank or primary literature
- Independent pharmacological plausibility assessment of titanium dioxide as a therapeutic agent (not merely an excipient) for bone metabolism, ophthalmic, or metabolic indications
- If no plausible MOA can be established, recommend excluding this candidate from further repurposing evaluation rather than continuing to Hold
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.